FindMyKOL
Clinical trialNCT02955290Active, not recruitingPhase 1/PHASE2Interventional

CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer

SponsorRoswell Park Cancer InstituteEnrollment51Advanced Head and Neck Squamous Cell CarcinomaAdvanced Squamous Non-Small Cell Lung CarcinomaLung Non-Small Cell CarcinomaMetastatic Lung Non-Small Cell CarcinomaPD-L1 PositiveRecurrent Head and Neck Squamous Cell Carcinoma+10 more conditions
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase I/II trial studies the best dose and side effects of recombinant human EGF-rP64K/montanide ISA 51 vaccine (CIMAvax) and nivolumab and to see how well they work in treating patients with non-small cell lung cancer or squamous head and neck cancer that has spread to other places in the body. Vaccine therapy, such as CIMAvax vaccine may help slow down and stop tumor growth. Immunotherapy with monoclonal antibodies, such as nivolumab and pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving CIMAvax vaccine together with nivolumab or pembrolizumab may work better in treating patients with non-small cell lung cancer or squamous head and neck cancer.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center

    Indianapolis, Indiana, United States

  • Roswell Park Cancer Institute

    Buffalo, New York, United States

  • St. Francis Hospital

    Roslyn, New York, United States

  • Good Samaritan Hospital

    West Islip, New York, United States

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Nivolumab →Pembrolizumab →Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
22 Dec 2016
Primary completion
25 Nov 2026
Completion
9 Dec 2027
Last update posted
10 Aug 2026
Registered enrollment
51
Registry id
NCT02955290
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.